Dr. Alan Durkin, a dual board-certified plastic and reconstructive surgeon and the founder of Ocean Drive Plastic Surgery in Vero…
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone…
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of…
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase…
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10…
Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc…
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that…
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin…
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with…
LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is…